Context: Reliable thyroglobulin (Tg) autoantibody (TgAb) detection before Tg testing for differentiated thyroid cancer (DTC) is critical when TgAb status (positive/negative) is used to authenticate sensitive second-generation immunometric assay ( 2G IMA) measurements as free from TgAb interference and when reflexing "TgAb-positive" sera to TgAb-resistant, but less sensitive, Tg methodologies (radioimmunoassay [RIA] or liquid chromatography-tandem mass spectrometry [LC-MS/MS]).
S
erum thyroglobulin (Tg) is the primary biochemical tumor marker used to detect recurrence in patients with differentiated thyroid cancers (DTCs) (1) . Unfortunately, the thyroglobulin autoantibodies (TgAbs) present in 25% to 30% of patients with DTCs can interfere with Tg measurement (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Automated (second-generation) immunometric assays ( 2G IMAs) are rapidly becoming the standard of care because they have superior functional sensitivity (FS) (0.05-0.10 g/L) for detecting basal Tg without recombinant human TSH stimulation (9, (12) (13) (14) (15) (16) (17) (18) . However, TgAb interference with Tg 2G IMAs causes underestimated (falsely low/undetectable) Tg 2G IMA (10, 11, 19) . In contrast, the radioimmunoassay (RIA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) classes of Tg methods resist TgAb interference but have an order of magnitude inferior FS (0.5-1.0 g/L), lack automation, and are not universally available (4, 6, 7, 9, 11, 12, 17, 19, 20) .
Laboratories often reflex Tg measurement to RIA or LC-MS/MS when the serum TgAb concentration is above a fixed cutoff set to define TgAb "positivity." This strategy is designed to maximize clinical sensitivity by restricting Tg 2G IMA measurement to "TgAb-negative" sera, while minimizing interference by reflexing "TgAb-positive" sera to a TgAb-resistant Tg methodology (RIA or LC-MS/MS) (6, 11, 19, 20) . Clearly, the sensitivity and specificity of the TgAb method has a critical impact on the reliability of this reflex strategy, because false-negative TgAb tests can lead to inappropriately low/undetectable Tg 2G IMA that can mask disease, whereas false-positive TgAb tests may prompt unnecessary reflexing to a less sensitive methodology that may fail to detect low Tg disease (21) (22) (23) (24) (25) (26) (27) . Guidelines caution against unnecessarily changing Tg methods because of wide disparities in numeric Tg values reported by different methods for the same serum (9, 12, 17, 18, 28 -30) .
Studies use concordance between TgAb methods to assess the reliability of TgAb detection (2, 10, (31) (32) (33) (34) (35) . This study directly evaluated the effects of interfering TgAbs on Tg measurement in terms of a low ratio (Ͻ75%) between values reported by a TgAb-sensitive Tg 2G IMA and a TgAb-resistant TgRIA (2, 10, 11, 17, 36, 37) . The Kronus TgAb method was selected for testing because this semiautomated radioassay predates current automated TgAb tests and has provided stable TgAb values for more than 2 decades (4). The Roche TgAb method was selected because laboratories adopted this method (38) after our previous study (10) found it to be more sensitive than 2 other automated TgAb tests (Beckman and Siemens) compared with Kronus as the reference.
Sensitivity differences between TgAb methods reflect the assay design, the specificity of the TgAb test reagents, and the cutoff selected to define a "positive" TgAb result. Previously, we reported that manufacturer-recommended cutoffs (MCOs) for TgAbs were set too high to reliably detect interfering TgAbs and were more appropriate for diagnosing thyroid autoimmunity (10) . The goals of the current study were to assess whether lower cutoffs could reduce false-negative and minimize false-positive TgAb misclassifications that could have a negative impact on DTC monitoring when a fixed TgAb cutoff value was used to reflex Tg testing to different methods.
Materials and Methods

Tg methods
Both Tg methods were standardized against the International Reference Preparation CRM-457.
TgRIA
This TgRIA, developed by the USC Endocrine Laboratory, University of Southern California, Los Angeles (4, 10, 28, 39) had first-generation FS (0.5 g/L) established by guidelines (Tg assay FS being the lowest Tg concentration measured with 20% between-run coefficient of variation [CV] in human serum over 6 -12 months [clinical interval typical for DTC monitoring] employing Ն2 different reagent lots and calibrators [30] ). Betweenrun precisions for TgAb-positive human sera measured over 1 year were 14.6%, 7.6%, 6.5%, 9.3%, and 7.8% for Tg concentrations of 0.75, 3.2, 12.0, 20.3, and 34.8 g/L, respectively. Within-run precisions were 8.4%, 7.1%, 1.5%, and 5.3% at Tg concentrations of 0.94, 2.0, 16.1, and 31.6 g/L, respectively.
Tg
2G
IMA
This Tg 2G IMA method was the Access immunochemiluminometric method (Beckman Coulter). The FS established for TgAb-negative human serum was 0.05 g/L. However, this study considered values of Ͻ0.10 g/L "undetectable" in accord with other reports (15) . Between-run precisions for TgAb-negative human sera measured over a 14-month period were 13.0%, 6.5%, 4.2%, and 4.0% for Tg concentrations of 0.13, 0.59, 7.0, and 54 g/L, respectively. Within-run precisions were 4.1%, 3.2%, 1.7%, and 1.9% at Tg concentrations of 0.15, 0.76, 7.0, and 106 g/L, respectively.
TgLC-MS/MS
TgLC-MS/MS measurements were made by the Mayo Medical Laboratories (40) . The limit of quantitation (LOQ) (20% CV between runs made over 1 month) was 0.5 g/L (6, 9).
Tg
2G
IMA/TgRIA ratios: used to indicate TgAb interference A low Tg 2G IMA/TgRIA ratio (Ͻ75%) was considered to indicate TgAb interference as previously established (2, 10, 36, 37) . Sera with TgAb concentrations below any specific cutoff displaying a low Tg 2G IMA/TgRIA ratio were considered false negative. Conversely, sera with TgAb values more than or equal to the cutoff without a low Tg 2G IMA/TgRIA ratio were considered false positive. Sera with severe interference had unequivo-cally detectable TgRIA (Ն1.0 g/L) and undetectable (Ͻ0.10 g/L) Tg 2G IMA.
TgAb assays
Both TgAb assays claimed standardization against the World Health Organization International Reference Preparation IRP 65/93 and were performed according to the manufacturers' protocols.
Kronus/RSR TgAb (K)
Method K was a semiautomated radioassay (Kronus also known as RSR) that uses 125 I-labeled Tg to bind TgAb in a diluted (1:21) serum specimen. The TgAb-Tg 125 I-labeled complex is precipitated with protein A. Between-run precisions for human sera measured over 1 year were 14.3%, 9.5%, 8.7%, and 11.1% for TgAb concentrations of 0.7, 2.6, 5.2, and 11.0 kIU/L, respectively. TgAb concentrations of Ͼ17 kIU/L were remeasured at appropriate dilutions. Within-run precisions of TgAb measured in human sera were 5.7%, 3.1%, 1.9%, and 3.1% at concentrations of 0.8, 3.0, 6.2, and 14.6 kIU/L, respectively. The LOD (within-run precision of zero matrix [41] ) was 0.3 kIU/L. FS, determined as for Tg (30) 
Roche Elecsys TgAb (R)
Method R was the automated electrochemiluminescent competitive immunometric assay method (Roche Diagnostics) whereby serum TgAb competes for biotinylated human Tg with ruthenium-labeled TgAb. The Tg-TgAb complexes form and bind streptavidin-coated microparticles and are magnetically captured onto the surface of an electrode. Between-run precisions for human sera measured over 1 year were 22.5%, 20.1%, 13.1%, 9.3%, 14.5%, 8.9%, and 16.7% for concentrations of 13, 17, 27, 35, 87, 146 , and 1329 kIU/L, respectively. Withinrun precisions were 4.9%, 5.1%, and 5.6% at concentrations of 63, 115, and 2894 kIU/L, respectively. Values of Ͼ4000 kIU/L were not diluted. The LOD was 10 kIU/L, and the FS of 22 kIU/L used by other laboratories (38) was confirmed. The MCO for a positive TgAb was 115 kIU/L.
Serum specimen groups
Group A comprised 89 sera from patients with DTC (88 papillary and 1 Hurtle cell) drawn a median of 8 days (range, 0 -167 days) before detection of persistent/recurrent disease by biopsy or anatomic imaging. Group A was used to compare the different classes of the Tg methods (Tg 2G IMA, TgRIA, and TgLC-MS/ MS). Of the patients, 37 were TgAb negative (below method K and R FSs), and 52 were classified as TgAb positive by both methods. Group B comprised 1426 sera from 1110 patients with DTC selected for sufficient volume for Tg 2G IMA and TgAb (both K and R) with unequivocally detectable TgRIA (range, 1.0 -40 g/L), allowing Tg 2G IMA/TgRIA ratio calculations. Group B sera were selected to cover a range of TgAb values from the LOD to very high TgAb concentrations. Group C comprised 607 sequential DTC sera received for routine Tg ϩ TgAb testing that had K and R TgAb measurements and were used to establish the range and frequency of TgAb values typical of clinical practice.
Serum TgAb analyses using different cutoffs for TgAb positivity
Methods K and R TgAb data for groups B and C were analyzed as subgroups covering the measurement range. Cutoffs for TgAb positivity represented those frequently used by laboratories: LOD, FS, receiver operating characteristic (ROC) curve, and MCO. For method K, these cutoffs were 0.3 (LOD), 0.4(FS), 0.5, 0.6, 0.7 (ROC curve), 0.8, 0.9, 1.0 (MCO), 1.2, 1.5, 2, 3, 5, 10, 25, 50, 100, and Ն 250 kIU/L, and for method R the cutoffs were 10 (LOD), 15, 18, 20, 22 
Statistical analyses
ROC curve analysis was performed using MedCalc 12.3.0 (Mariakerke) software. A true-positive serum had TgAb values more than or equal to the selected cutoff with an abnormally low Tg 2G IMA/TgRIA ratio (Ͻ75%) indicating TgAb interference (2, 10, 17, 36, 37) . A false-positive serum had TgAb values more than or equal to the selected cutoff without a low Tg 2G IMA/ TgRIA ratio (Ն75%) indicating the absence of TgAb interference. A true-negative serum had TgAb below the cutoff without a low Tg 2G IMA/TgRIA ratio. A false-negative serum had TgAb below the cutoff with a low Tg 2G IMA/TgRIA ratio. Statistical analyses were performed with XLSTAT and Student t tests using SPSS software (version 13.0). Statistical significance was set at a value of P Ͻ .05. IMA ϭ 0.96TgRIA Ϫ 0.3, r ϭ0.95). Although the Tg 2G IMA/TgRIA ratios for group A TgAb-negative sera were variable, overall they were comparable to those for group B TgAb-negative sera (101 Ϯ 19% vs 83 Ϯ 32%, group B vs group A, respectively, NS). When TgAb was detected, Tg 2G IMA was frequently lower than TgRIA, and 25% of sera exhibited severe interference (Tg 2G IMA of Ͻ0.10 g/L) ( Figure 2B ). The table in Figure 2 shows that the relationship between TgRIA and severe interference was independent of the TgAb concentration and occurred with higher frequency (39%) at low TgRIA (1.0 -2.5 g/L) than at high (Ͼ10 g/L) TgRIA (4%). Figure 3 (top panels) shows TgAb method K vs R subgroup analyses for the 607 sequential sera (group C). With use of the FS cutoffs, the percentage classified as TgAb positive was comparable (42.6% vs 46.7%, K vs R, respectively, NS), but higher than previously reported for DTC (20%-30%) (2, 3) . This reflected the use of FS cutoffs as opposed to the MCOs employed by earlier studies (2) as well as preferential ordering for the TgRIA methodology used by this laboratory. Of the group C sera, 66% had low (Ͻ1.0 g/L) Tg (both TgRIA and Tg 2G IMA), 30% had TgRIA between 1 and 40 g/L (median, 3.0 g/L), and only 4% had TgRIA of Ͼ40 g/L. Four specimens with Tg of Ͼ1000 g/L (both Tg 2G IMA and TgRIA)
Results
were classified as TgAb positive by method R (23, 26, 33 , and 148 kIU/L) but TgAb negative by method K, confirming other reports that high Tg concentrations interfere, causing false-positive method R values (33) . Figure 3 (bottom panels) shows Group B subgroup frequencies for false-positive and false-negative TgAb misclassifications using different method K vs R cutoffs ranging from the LOD to high TgAb concentrations and using low Tg 2G IMA/TgRIA ratios (Ͻ75%) to indicate interfer- ing TgAb. IMA/TgRIA ratios. The frequency of severe interference steadily rose with the increasing cutoff to peak at ϳ15% at high TgAb concentrations. ROC curve analysis (Figure 4 ) reported optimal cutoffs of Ͼ0.6 kIU/L for method K vs Ͼ40 kIU/L for method R and showed that method K had higher sensitivity for TgAb detection (81.9% vs 69.1%, K vs R, respectively, P Ͻ .001) and more area under the curve (0.89 vs 0.85, respectively, P Ͻ .001). With ROC curve cutoffs of 0.7 kIU/L (K) vs 41 kIU/L (R), method K classified fewer sera as TgAb negative (46.3% vs 55.1%, K vs R, respectively, P Ͻ .001) of which fewer were false negatives (21.7% vs 31.6%, K vs R, respectively, P Ͻ .001). Furthermore, fewer false-negative sera displayed severe interference using method K (2.1% vs 6.2%, K vs R, respectively, P Ͻ .001). When the FS cutoff recommended by guidelines (30) was used, method K also displayed superior sensitivity. Specifically, although the percentage of TgAb negatives was comparable using FS cutoffs (32.1% vs 34.9%, K vs R, respectively, NS), fewer method K TgAb negatives were false negatives (13.5% vs 21.3%, K vs R, respectively, P Ͻ .01) and fewer displayed severe interference (0.7% vs 2.4%, K vs R, respectively, P Ͻ .05). In addition, using method K, fewer false-negative sera had inappropriately low Tg 2G IMA (Ͻ0.30 g/L) (0.7% vs 4.4%, K vs R, respectively, P Ͻ .001). Consistent with superior method K sensitivity, fewer method K false negatives were judged positive by method R compared with method R false negatives judged positive by method K (16.1% vs 50.9% K vs R, respectively, P Ͻ .001). A chart review revealed that a significant number of false-negative sera were from patients with DTC with a prior (method K) history of TgAb positivity (32.2% vs 20.8%, K vs R, respectively). Taken together, these data suggested that a low Tg 2G IMA/Tg RIA ratio detected interfering TgAb more sensitively than direct TgAb measurement using either method, as reported previously (37) . Methods K and R had comparable false-positive frequencies using FS cutoffs (22.4% vs 23.8%, K vs R, respectively, NS). However, method R had a wider subfunctional sensitivity range (10 -21 kIU/L) vs that for method K (0.1-0.3 kIU/L), suggesting a higher method R potential for reporting false positives using cutoffs of Ͻ22 kIU/L. (5, 17) . This study has clinical implications for laboratories that perform reflex Tg testing. The study confirmed that falsenegative TgAb misclassifications were unacceptably high (30%-40%) using the MCOs for TgAb (10), whereas the FS cutoff minimized both false negatives and severe interferences associated with falsely low/undetectable Tg 2G IMA. However, the FS cutoffs were associated with an approximate 20% false-positive frequency that could prompt unnecessarily reflexing of many sera to less sensitive RIA or LC-MS/MS methodology, which could fail to detect disease associated with low Tg concentrations (21) (22) (23) (24) (25) (26) (27) . The FS cutoff also has an inherent 20% between-run imprecision (30) that could lead to false fluctuations in TgAb status (positive to negative or vice versa) while monitoring patients with low TgAb concentrations and, as a result, prompt unnecessary changes in the Tg method used. Guidelines caution about the need for Tg method continuity, because different numeric Tg values are reported when the same serum sample is measured by different methods (4, 9, 12, 17, 28 -30). Although there were correlations between the methods in the absence of TgAb overall, the discordance between the Tg 2G IMA, TgRIA, and TgLC-MS/MS measurements made for the individual TgAb-negative patients with disease was higher (mean 24% CV, range 0%-100%) than would be typical when Tg 2G IMA is used consistently to monitor an individual patient at 6-to 12-month intervals (9). The 5 patients (14%) who displayed severe (Ͼ30% CV) between-method discordances (red circles in Figure 1A ) emphasize how serum Tg monitoring could be disrupted by unnecessarily Tg method changes. Laboratories that reflex Tg testing to different methods based on the TgAb FS cutoff could guard against unnecessarily changing the Tg method by considering the patient's Tg and TgAb testing history, in addition to the TgAb status of the current specimen, before selecting an appropriate Tg method.
This study evaluated how different Kronus/RSR vs Roche TgAb method cutoffs for positivity influenced TgAb false-negative and false-positive frequencies, using a low Tg 2G IMA/TgRIA ratio (Ͻ75%) to indicate the presence of interfering TgAb (2, 10, 36, 37) . Table 1 and Figure  3 show that false positives declined whereas false negatives rose with a rising cutoff, but that no cutoff used for either method eliminated all false-negative and false-positive TgAb misclassifications. ROC curve analysis reported higher Kronus sensitivity vs Roche sensitivity, although both the ROC curve-determined and manufacturer-recommended cutoffs of both methods had unacceptably high false-negative frequencies (20%-40%) that included many cases of severe interference (Tg 2G IMA of Ͻ0.10 g/L) (10, 33, 34) . This is the first study of TgLC-MS/MS Figure  1B ) and lower Tg 2G IMA vs either TgLC-MS/MS or TgRIA seen for an additional 60% of these patients. The paradoxically undetectable TgLC-MS/MS seen for 12 of 52 (23%) TgAb-positive patients despite the presence of disease warrants further study. Two of these patients had no Tg detected by any method, and 8 had undetectable Tg 2G IMA and TgLC-MS/MS but unequivocally detectable (Ն1.0 g/L) TgRIA. It was more common to see TgAb-positive sera with TgRIA higher (Ͼ50%) than TgLC-MS/MS than sera with higher TgLC-MS/MS than TgRIA (56% vs 11%, respectively, P Ͻ .01), consistent with either TgAb interference causing TgRIA overestimation or false-positive TgRIA (42, 43) or, alternatively, the presence of a polymorphic tumor Tg that failed to generate the target Tg peptide necessary for LC-MS/MS detection (20) . It was striking that both TgLC-MS/MS and TgRIA values were significantly lower (P Ͻ .001) when patients with disease had TgAb detected (Figure 1, B vs A) . This observation lends support to past studies, suggesting that increased metabolic clearance of Tg-TgAb complexes may be responsible (5, 44 -47) . If the metabolic clearance of Tg complexed with TgAb is faster than the clearance of free Tg, high Tg assay FS would be especially critical for detecting disease in TgAb-positive patients (22, 26) .
Guidelines mandate that each DTC specimen have a TgAb status determined directly by immunoassay and not a Tg recovery test (1, 5, 6, 17, 28, 30 (4, 10, 12, (31) (32) (33) (34) (35) . This study of 2 well-established TgAb methods (Kronus/RSR vs Roche) found that both the intrinsic sensitivity of the method and the cutoff selected for TgAb positivity influenced the reliability of TgAb detection. In addition, Tg concentrations of Ͼ1000 g/L interfered with the Roche method, as described previously (33) . Some sera were classified as TgAb positive by one method but TgAb negative by the other, and some low TgAb concentrations caused profound interference whereas high TgAb in other sera appeared nonreactive (2, 5, 10, 17, 48) . These qualitative TgAb differences reflect a complex matrix of factors that include the numeric cutoff for positivity (10, 33, 34) as well as the epitope specificity of the individual patient's serum Tg antibodies for binding the thyroglobulin reagent used in the TgAb test (10, 33, 35, 48 -50) . Comparative TgAb method studies fail to assess how Tg antibodies in individual sera affect Tg measurement (10, (31) (32) (33) (34) (35) . Either a positive TgAb test and/or discordant Tg results between different analytical methods (eg, Tg 2G IMA vs TgRIA) are recognized indicators for possible Tg interference (18) . The current study used an abnormally low Tg 2G IMA/ TgRIA ratio (Ͻ75%) to assess the influence of interfering TgAb on Tg measurement, as reported previously (2, 5, 10, 18, 36, 37, 51) . This Tg 2G IMA/TgRIA ratio parameter had the advantages of being independent of the measured TgAb concentration as well as the potential to amplify TgAb influences by distorting Tg 2G IMA and TgRIA values in opposite directions. Thus, the unidirection (underestimation) typical of TgAb interference with IMA, coupled with either an unaffected or overestimated TgRIA, would produce a lower Tg 2G IMA/TgRIA ratio (2, 4, 9, 10, 36, 37). Although specimen availability and cost constraints prevented the use of Tg 2G IMA/TgLC-MS/MS ratios for the entire study, the utility of the Tg 2G IMA/TgRIA ratio parameter is supported by the concordance found between ratios calculated for patients with disease ( Figure  1 ) using either TgRIA or TgLC-MS/MS as the denominator. Specifically, when Tg was detectable, making ratio calculations possible, the Tg 2G IMA/TgRIA vs Tg 2G IMA/ TgLC-MS/MS ratios were comparable both in the presence and absence of TgAb. It should be noted that the group A TgAb-negative patients with disease displayed a wider range of Tg 2G IMA/TgRIA ratios than that seen for group B TgAb-negative results that comprised a larger number of sera but probably included fewer patients with disease (with no clinical information available). The wider range of Tg 2G IMA/TgRIA ratios seen for the group A TgAb-negative patients reflected the discordances seen between the 3 methods that characterized these patients ( Figure 1A ) and probably reflected different method specificities for detecting heterogeneous, tumor-derived, Tg molecules (51) .
When FS cutoffs were used, the Roche method reported significantly more false negatives with severe interferences than the Kronus method (2.4% vs 0.7%, R vs K, respectively, P Ͻ .05), and more false negatives with inappropriately low (Ͻ0.30 g/L) Tg
2G
IMA values (4.4% vs 0.7%, R vs K, respectively, P Ͻ .001). Underestimation causing falsely low (but detectable) Tg 2G IMA values has as much potential to disrupt clinical management as severe interference, because a Tg 2G IMA of Ͻ0.30 g/L predicts the absence of disease (14 -16, 18, 24, 25, 27, 29) . Now that radioiodine remnant ablation is no longer considered a necessary treatment for low-risk DTC (52) (53) (54) (55) (56) , an increasing number of disease-free patients will undergo lifelong monitoring of low basal (non-TSH-stimulated) Tg 2G IMA concentrations (0.10 -1.0 g/L range) arising from normal remnant tissue (9, 24, 25, 27, 57, 58) . TgAb positivity is associated with a higher DTC recurrence risk (59 -62) and changes in a patient's TgAb status have clinical implications: a TgAb decline or disappearance is considered a good prognostic sign, whereas a rise in or de novo appearance of TgAb suggests active disease (2-7, 59, 60, 63-68 This study has a number of clinical implications. It is the first to show that a detectable or higher TgLC-MS/MS is frequently seen for TgAb-positive patients with persistent/ recurrent DTC and undetectable/low Tg 2G IMA (11, 19, 20) , confirming that TgAb interference causing Tg 2G IMA underestimation can mask disease ( Figure 1B) . The study emphasizes how concordance between Tg 2G IMA and Tg measured by a different class of method (RIA or LC-MS/MS) may help prove that a Tg 2G IMA result is free from TgAb interference (17, 18) . The primary focus of the study was the influence of TgAb method cutoffs on the reliability of TgAb detection. No cutoff could be identified for either the Kronus or Roche TgAb method that eliminated both false-negative and false-positive serum TgAb misclassifications. Because TgAb interference causing Tg 2G IMA underestimation is considered the most serious clinical problem, it is optimal to use the FS cutoff to define TgAb positivity because this cutoff minimizes false negatives. However, a significant percentage of sera (ϳ20%) would be misclassified as TgAb-positive using FS and could be unnecessarily reflexed to the less sensitive TgRIA or TgLC-MS/MS methodologies that may fail to detect disease associated with low Tg concentrations (21) (22) (23) (24) (25) (26) (27) . In addition, use of the FS cutoff can cause the TgAb status of patients with low TgAb concentrations to fluctuate between "negative" and "positive" over time, as a result of assay imprecision (15%-20%) exacerbated by the TgAb biologic variability (ϳ15%) expected during DTC monitoring (69) . Changes in a patient's TgAb status that were solely methodologic could prompt unnecessary switching between Tg methodologies (Tg 2G IMA to TgRIA or TgLC-MS/MS, or vice versa) and potentially disrupt serial Tg monitoring, thereby negatively affecting clinical management. The potential for disrupting Tg monitoring is clearly evident from the significant serum Tg 2G IMA, TgRIA, and TgLC-MS/MS differences seen in Figure 1A that appear unrelated to TgAb and possibly reflect method specificity differences for tumor Tg detection. Laboratories that reflex Tg testing to different methods should minimize unnecessary Tg method changes by considering the individual patient's Tg and TgAb measurement history in addition to the TgAb status of the current specimen before selecting an appropriate Tg method and establishing a new baseline for patients when a change in the Tg or TgAb method becomes necessary. Physicians should recognize the technical limitations of the current Tg and TgAb measurements illustrated by this study and interpret serum Tg and TgAb values relative to the clinical status of the patient.
